Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative Efgartigimod with Thymectomy for MG and Thymoma
NCT06221501Phase 2Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Feb 2024
- Primary completion
- Dec 2026
- Modality
- Antibody Fragments
01
Overview
A Phase 2 trial of efgartigimod alfa in myasthenia gravis (MG), sponsored by Zhongshan Hospital, Fudan University. Planned start Feb 2024; status: not yet recruiting.
02
Drugs
efgartigimod alfa
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT06221501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06221501.